# Shinobi Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shinobi-therapeutics

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.shinobitx.com
- Total disclosed funding: $78M
- Latest round: Series A (Aug 15, 2024)
- Investors on record: 9

## About

Based in California, US, and co-founded in 2023 by Tobias Deuse and Shin Kaneko, Shinobi Therapeutics Inc., a.k.a. Shinobi operates a biotechnology company that focuses on developing a new class of immune-evasive iPS-T cell therapies for cancer treatment. In December 2023, Shinobi Therapeutics Inc. raised USD 51 million in a Series A co-led by EQT Life Sciences, F-Prime Capital, and Eight Roads Ventures Japan, with participation from Astellas Venture Management, Fast Track Initiative, JIC Venture Growth Investments, and D3 LLC. As of January 2023, the firm is led by its CEO, Daniel Kemp.

The company's flagship product, Katana platform, facilitates the creation of immune evasive CD8?ß iPS-T cells. These cells, with plug-and-play antigen specificity, offer cancer treatment by providing increased persistence, reduced lymphodepletion, redosability, and off-the-shelf availability. The company’s product line includes NJA-001 (CD8?ß T cell), NJA-002 (CD8?ß T cell), NJA-003 (CD8?ß T cell), NJA-004 (CD8?ß T cell), and NJA-005 (pancreatic beta cell) used for iPSC-derived cell therapies.

The company plans to use its proceeds from December 2023 funding to advance Katana's iPS-T cell therapy platform and progress the first program to treat GPC3+ solid tumor cancers toward the clinic.

## Funding rounds

- Series A, Aug 15, 2024, $45M — Mitsubishi UFJ Capital, Yosemite Management
- Series A, Dec 12, 2023, $34M — EQT Life Sciences, Astellas Venture Management, F-Prime Capital, Eight Roads Ventures Japan (Inactive), Fast Track Initiative, D3 LLC, JIC Venture Growth Investments

## Investors

- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A
- Astellas Venture Management (https://capitalatlas.ai/funds/astellas-venture-management) — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- Eight Roads Ventures Japan (Inactive) — Series A
- Fast Track Initiative (https://capitalatlas.ai/funds/fast-track-initiative) — Series A
- D3 LLC (https://capitalatlas.ai/funds/d3-llc) — Series A
- JIC Venture Growth Investments (https://capitalatlas.ai/funds/jic-venture-growth-investments) — Series A
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series A
- Yosemite Management (https://capitalatlas.ai/funds/yosemite-management) — Series A